Epilepsy

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 28, 2025.

Emma Macdonald-Laurs, PhD, FRACP, MBChB, a neurologist at the Royal Children’s Hospital in Melbourne, Australia, provided commentary on the progress and challenges the epilepsy community faces amid Purple Day.

Luis Tornes, MD, a neurologist and director of Baptist Health’s Epilepsy Program, provided clinical insights on raising awareness for Purple Day, a global initiative dedicated for patients and families with epilepsy.

Explore the key 2024 neurology guideline updates shaping clinical care across stroke, epilepsy, movement disorders, and more in this essential feature.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology news headlines you may have missed over the course of February 2025, compiled all into one place by the NeurologyLive® team.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sonal Bhatia, MD, FACNS. [LISTEN TIME: 24 minutes]

Amber Freed, founder of SLC6A1 Connect, shared her personal journey and advocacy efforts to raise awareness for SLC6A1, a rare genetic epilepsy, in honor of Rare Disease Day.

Here's some of what is coming soon to NeurologyLive® this week.

Pathogenic variants in the CACNA1A, ATP1A2, and SCN1A genes were associated with a higher risk of migraine, particularly in heterozygous carriers of loss-of-function and neutral variants.

Zorevunersen, an antisense oligonucleotide, is currently being evaluated in a phase 3 registrational trial, with data expected in the second half of 2027.

Findings showed that patients with epilepsy were significantly more likely to experience a range of psychiatric disorders, including depression, anxiety, and substance use disorders, compared with those without the condition.

Jonathon Parker, MD, PhD, an assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona, provided commentary on the promise and roadblocks behind stem cell approaches in epilepsy.

Here's some of what is coming soon to NeurologyLive® this week.

Expected to conclude in late 2026, the trial will feature 30 patients with Jordan’s syndrome, aged 9-45 years, who will be tested for a 24-week treatment period.

Here's some of what is coming soon to NeurologyLive® this week.

Over a 52-week treatment period, patients who continued on bexicaserin and those who switched from placebo demonstrated notable decreases in motor seizures, further supporting the agent’s development.

Catch up on any of the neurology news headlines you may have missed over the course of January 2025, compiled all into one place by the NeurologyLive® team.

Jacqueline A. French, MD, a professor of neurology at the NYU Grossman School of Medicine, provided clinical perspectives on her experiences and career growth in neurology amid National Women Physicians Day.

Here's some of what is coming soon to NeurologyLive® this week.

Neal K. Shah talked about an artificial intelligence innovation that can be used to fight denied health insurance claims, thus improving revenue cycle management for physicians' practices and the patient experience.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 31, 2024.

Explore some of the most highly anticipated clinical trials with data readouts expected in the second half of 2025—key updates that researchers and clinicians in neurology won’t want to miss.

A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]

The medical director of the Arkansas Children’s Comprehensive Epilepsy Program discussed the complications associated with neurostimulation in patients with LGS and strategies to mitigate these issues. [WATCH TIME: 2 minutes]